253 related articles for article (PubMed ID: 14532275)
1. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
[TBL] [Abstract][Full Text] [Related]
2. Specificity of binding with matrix metalloproteinases.
Gupta SP; Patil VM
Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
[TBL] [Abstract][Full Text] [Related]
3. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1.
Welch AR; Holman CM; Huber M; Brenner MC; Browner MF; Van Wart HE
Biochemistry; 1996 Aug; 35(31):10103-9. PubMed ID: 8756473
[TBL] [Abstract][Full Text] [Related]
4. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure.
Lang R; Kocourek A; Braun M; Tschesche H; Huber R; Bode W; Maskos K
J Mol Biol; 2001 Sep; 312(4):731-42. PubMed ID: 11575928
[TBL] [Abstract][Full Text] [Related]
5. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
[TBL] [Abstract][Full Text] [Related]
6. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
[TBL] [Abstract][Full Text] [Related]
7. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
8. Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
Baidya SK; Banerjee S; Adhikari N; Jha T
J Med Chem; 2022 Aug; 65(16):10709-10754. PubMed ID: 35969157
[TBL] [Abstract][Full Text] [Related]
9. Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26.
Park HI; Turk BE; Gerkema FE; Cantley LC; Sang QX
J Biol Chem; 2002 Sep; 277(38):35168-75. PubMed ID: 12119297
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.
Lovejoy B; Welch AR; Carr S; Luong C; Broka C; Hendricks RT; Campbell JA; Walker KA; Martin R; Van Wart H; Browner MF
Nat Struct Biol; 1999 Mar; 6(3):217-21. PubMed ID: 10074939
[TBL] [Abstract][Full Text] [Related]
14. Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.
Wasserman ZR; Duan JJ; Voss ME; Xue CB; Cherney RJ; Nelson DJ; Hardman KD; Decicco CP
Chem Biol; 2003 Mar; 10(3):215-23. PubMed ID: 12670535
[TBL] [Abstract][Full Text] [Related]
15. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate.
Meng Q; Malinovskii V; Huang W; Hu Y; Chung L; Nagase H; Bode W; Maskos K; Brew K
J Biol Chem; 1999 Apr; 274(15):10184-9. PubMed ID: 10187802
[TBL] [Abstract][Full Text] [Related]
16. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily.
Dhanaraj V; Ye QZ; Johnson LL; Hupe DJ; Ortwine DF; Dunbar JB; Rubin JR; Pavlovsky A; Humblet C; Blundell TL
Structure; 1996 Apr; 4(4):375-86. PubMed ID: 8740360
[TBL] [Abstract][Full Text] [Related]
17. Contribution of lysine 60f to S1' specificity of thrombin.
Rezaie AR; Olson ST
Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics.
Hou T; Zhang W; Xu X
J Comput Aided Mol Des; 2002 Jan; 16(1):27-41. PubMed ID: 12197664
[TBL] [Abstract][Full Text] [Related]
20. The effect of changing the hydrophobic S1' subsite of thermolysin-like proteases on substrate specificity.
de Kreij A; van den Burg B; Veltman OR; Vriend G; Venema G; Eijsink VG
Eur J Biochem; 2001 Sep; 268(18):4985-91. PubMed ID: 11559368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
